UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): May 29, 2018

 

 

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		000-50679		77-0487658
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former, address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

---

Item 5.07

Submission of Matters to a Vote of Security Holders

On May 29, 2018, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2019 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

A total of 115,235,013 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 18, 2018 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 108,841,664. The voting on the two matters is set forth below:

Proposal 1 – Election of Directors. The following directors were elected to serve until our 2019 annual meeting of stockholders and until their successors are elected and qualified.

 

Director		For				Withheld				Broker Non-Votes
James N. Wilson			79,901,234				533,210				28,407,220
G. Leonard Baker, Jr.			79,906,775				527,669				28,407,220
Joseph K. Belanoff, M.D.			80,036,906				397,538				28,407,220
Daniel M. Bradbury			79,687,700				746,744				28,407,220
Reneé D. Galá			79,871,055				563,389				28,407,220
David L. Mahoney			77,158,123				3,276,321				28,407,220
Daniel N. Swisher, Jr.			80,092,227				342,217				28,407,220

Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

For			107,929,017
Against			849,787
Abstain			62,860
Broker Non-Votes			N/A

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 4, 2018